Maintenance antipsychotic drugs do prevent relapse: a reply to Tobias and MacDonald.
D014150:Antipsychotic Agents / Q000627:therapeutic use*; D002746:Chlorpromazine / Q000627:therapeutic use; D002908:Chronic Disease; D004341:Drug Evaluation; D005476:Fluphenazine / Q000627:therapeutic use; D006801:Humans; D010546:Perphenazine / Q000627:therapeutic use; D010919:Placebos; D011346:Prochlorperazine / Q000627:therapeutic use; D012008:Recurrence; D012107:Research Design; D012559:Schizophrenia / Q000517:prevention & control*; D013375:Substance Withdrawal Syndrome; D013881:Thioridazine / Q000627:therapeutic use; D014268:Trifluoperazine / Q000627:therapeutic use
D014150:Antipsychotic Agents; D010919:Placebos; D014268:Trifluoperazine; D010546:Perphenazine; D013881:Thioridazine; D005476:Fluphenazine; D002746:Chlorpromazine; D011346:Prochlorperazine